sutent
(Sunitinib malate)Pfizer Laboratories Div Pfizer Inc
Usage: SUTENT is indicated for treating adult patients with gastrointestinal stromal tumors after imatinib progression or intolerance, advanced renal cell carcinoma, adjuvant treatment of high-risk recurrent renal cell carcinoma post-nephrectomy, and progressive well-differentiated pancreatic neuroendocrine tumors in advanced or metastatic stages.